Potentially inappropriate medication use in hospitalized elderly patients

Regina Maria Alexandre Fernandes de Oliveira¹*, Milton Luiz Gorzoni², Ronaldo Fernandes Rosa²

SUMMARY

OBJECTIVE: This study aimed to assess the prevalence of potentially inappropriate medication prescription in hospitalized elderly patients according to the 2019 American Geriatrics Society Beers Criteria.

METHODS: This study is a prospective analysis of electronic medical records of elderly patients admitted to the Department of Medicine, Hospital Central da Irmandade da Santa Casa de Misericórdia de São Paulo, between 1 September 2020 and 30 April 2021.

RESULTS: A total of 142 patients (85 women and 57 men) with a mean age of 74.5±7.3 years (65–99 years) were assessed. Of these, 108 (76.1%) were elderly (age ≥65 years and <80 years) and 34 (23.9%) long-lived (age ≥80 years). The average length of stay found in the sample was 25.3±28.7 days (between 2 and 235 days), and 102 out of the 140 patients assessed remained in the hospital for up to 29 days. Sixteen drugs considered potentially inappropriate medication were found in the patients’ prescriptions, with at least one potentially inappropriate medication having been prescribed to 141 (99.3%) patients. Elderly patients had a mean of 2.57±0.94 potentially inappropriate medication prescribed versus 2.56±0.89 among long-lived patients. The most prescribed potentially inappropriate medication were as follows: regular human insulin as required (85.2%), and omeprazole (73.9%) and metoclopramide as required (61.3%).

CONCLUSION: The study sample showed significant percentages of potentially inappropriate medication prescriptions for the elderly admitted to the hospital.

KEYWORDS: Potentially inappropriate medication list. Inpatients. Side effects. Hospitalization. Aged. Iatrogenic disease. Inappropriate prescribing.

INTRODUCTION

The number of elderly people and life expectancy worldwide have both increased significantly. This characterizes the phenomenon of aging, in which the population aged 65 years and older grows at a rate of about 3% per year, a rate that is higher than those in any other age group¹,².

Aging consists of a progressive inability to maintain the homeostatic balance and is associated with the decline of organic functions, which results in a predisposition of the elderly population to develop multiple comorbidities. In turn, the direct consequence of this scenario is a higher prevalence of older adults being hospitalized, in which a wide variety of drugs are used in addition to those chronically used by them³,⁴.

The elderly population, however, has a number of age-specific conditions that influence drug metabolism and pharmacokinetics thereof. Thus, both first-pass metabolism and hepatic clearance can be altered, which increases the bioavailability of xenobiotics in the elderly. Furthermore, changes in body composition occur with age, and lipophilic drugs may have a greater distribution volume with a longer half-life, whereas hydrophilic drugs have a lower distribution volume. Finally, renal function is globally reduced, as the vast majority of elderly people have some degree of renal dysfunction⁵,⁶.

In this context, the concept of potentially inappropriate medication (PIM) use in the elderly must be taken into account⁷, and the use thereof represents greater risks of causing adverse reactions to patients due to the changes inherent to aging. Therefore, lists have been created in order to assist clinical practitioners in identifying PIM and preventing their prescription⁸-¹⁰.

The so-called “Beers criteria” of the American Geriatrics Society (AGS), developed by an American team of specialists, comprising, among others, geriatricians, pharmacologists, and clinical pharmacists, is one of those lists that are readily available.

¹Irmandade da Santa Casa de Misericórdia de São Paulo, School of Medical Sciences – São Paulo (SP), Brazil.
²Irmandade da Santa Casa de Misericórdia de São Paulo, Internal Medicine Department – São Paulo (SP), Brazil.
*Corresponding author: reginamafo@gmail.com

Conflicts of interest: the authors declare there is no conflicts of interest. Funding: none.

Received on January 04, 2022. Accepted on March 26, 2022.
available and has become the most cited and used worldwide for detecting PIM\textsuperscript{11,12}.

Refaining from using PIM in the elderly is an important public health strategy, since it optimizes the appropriate prescription for this population, thereby preventing potentially negative outcomes such as predictable adverse drug reactions, prolonged hospital stay, disabilities, and death\textsuperscript{13,14}.

The goal of this study was to assess the prevalence of PIM use in hospitalized elderly patients according to the 2019 AGS Beers criteria\textsuperscript{15}.

**METHODS**

**Study design**

This is a prospective analysis of electronic medical records of elderly patients admitted to the Department of Medicine at Hospital Central da Irmandade da Santa Casa de Misericórdia de São Paulo (ISCMS) between September 1, 2020 and April 30, 2021.

For analysis, patients aged \( \geq 65 \) years, admitted to the internal medicine ward for 24 h or more and who were not receiving end-of-life palliative care or whose reason for admission was SARS-CoV-2 infection were included.

Those drugs listed in Table 1 (“Potentially Inappropriate Medication Use in Older Adults”) of the 2019 AGS Beers criteria were considered PIM. Such table was adapted according to the medications approved for use in Brazil as per data available from Brazil’s National Health Surveillance Agency (ANVISA, the Portuguese acronym for “Agência Nacional de Vigilância Sanitária”) website on October 28, 2021\textsuperscript{16} (Table 2).

An electronic form was created for receiving data taken from the patients’ medical records (Soul MV System, version 2.1).

### Table 1. Potentially inappropriate medicines identified in the sample.

| Potentially inappropriate medication | Female patients and age | Male patients and age | Total (142) | Percentage of use |
|-------------------------------------|-------------------------|-----------------------|-------------|------------------|
|                                     | Elderly (65) | Long-lived (20) | Elderly (43) | Long-lived (14) |          |          |
| Regular human insulin AR            | 54 | 18 | 36 | 13 | 121 | 85.2 |
| Omeprazole                          | 48 | 15 | 32 | 10 | 105 | 73.9 |
| Metoclopramide AR                   | 41 | 12 | 26 | 8  | 87  | 61.3 |
| Dimenhydrinate AR                   | 4  | 2  | 3  | 1  | 10  | 7.0  |
| Promethazine                        | 3  | –  | 2  | 1  | 6   | 4.2  |
| Amiodarone                          | 1  | 1  | 2  | 1  | 5   | 3.5  |
| Diazepam AR                         | 2  | –  | 1  | 1  | 4   | 2.8  |
| Dimenhydrinate                      | 3  | –  | 1  | –  | 4   | 2.8  |
| Phenobarbital                       | 1  | 2  | –  | –  | 3   | 2.1  |
| Amitriptyline                       | 1  | –  | 1  | –  | 2   | 1.4  |
| Clonazepam                          | 1  | –  | 1  | –  | 2   | 1.4  |
| Clonazepam AR                       | –  | –  | 2  | –  | 2   | 1.4  |
| Scopolamine                         | 1  | –  | 1  | –  | 2   | 1.4  |
| Scopolamine AR                      | 2  | –  | –  | –  | 2   | 1.4  |
| Hydroxyzine                         | 2  | –  | –  | –  | 2   | 1.4  |
| Metoclopramide                      | 2  | –  | –  | –  | 2   | 1.4  |
| Propantheline                       | –  | –  | 2  | –  | 2   | 1.4  |
| Diazepam                            | –  | –  | 1  | –  | 1   | 0.7  |
| Doxazosin                           | –  | –  | –  | 1  | 1   | 0.7  |
| Methyldopa                          | –  | 1  | –  | –  | 1   | 0.7  |
| Nifedipine                          | 1  | –  | –  | –  | 1   | 0.7  |

AR: as required.
Table 2. Medications licensed for use in Brazil listed in Table 2 of the 2019 American Geriatrics Society Beers criteria.

| Therapeutic class | Antidepressants | First-generation antihistamines | Antiparkinsonian drugs | Barbiturates | Antispasmodics | Nonsteroidal anti-inflammatory drugs | Benzodiazepines | Nonbenzodiazepine hypnotics (Z-drugs) | Muscle relaxants | Other cardiovascular action drugs | Antibiotics | Antithrombotic drugs | Gastrointestinal tract | Hypoglycemic drugs |
|-------------------|-----------------|---------------------------------|------------------------|-------------|----------------|-------------------------------|----------------|-----------------------------------|-----------------|-----------------------------|-------------|------------------|-------------------|------------------|
| Central alpha-agonists | Clonidine (for first-line treatment of hypertension) Guanabenz Guanfacine Methyldopa Reserpine (>0.1 mg/day) | Amitriptyline Amoxapine Clomipramine Desipramine Doxepin (>6 mg/day) Imipramine Nortriptyline Paroxetine Protriptyline Trimipramine | Brompheniramine Carboxamidine Chlorpheniramine Clemastine Cyproheptadine Dextrorphan Benztropine Dihydroergotamine (oral) Doxylamine Hydroxyzine Meclizine Pyrilamine or Mepyramine Promethazine Triprolidine | Benzatropine (oral) Trihexyphenidyl | Amobarbital Butalbital Butabarbital | Atropine (excludes ophthalmic use) Belladonna alkaloids Chloralhydratine clidinium Dicyclomine Homatropine (excludes ophthalmic use) Hyoscine Methocarbamol Propantheline Scopolamine | Acetylsalicylic acid (>325 mg/day) Mefenamic acid Ketoprofen Ketorolac (including parenteral) Diclofenac Diflunisal Etodolac Fenoprofen Ibuprofen Indomethacin Meclomenamate Meloxicam Nabumetone Naproxen Piroxicam Sulindac Tolmetin | Short or intermediate action: Alprazolam Estazolam Lorazepam Oxazepam Temazepam Triazolam Prolonged action: Chloralhydrate (alone or in association with amitriptyline or clidinium) Clonazepam Lorazepam Diazepam Flurazepam Quazepam | Eszopiclone Zaleplon Zolpidem | Carisoprodol Chlorzoxazone Cyclobenzaprine Methocarbamol Orphenadrine | Nitrofurantoin | Dipyridamole (oral, short-term) | Metoclopramide Mineral oil (oral) | Sulfonylureas of prolonged action Chlorpropamide Glibenclamide | Meperidine Vasodilators of dubious efficacy Ergotoid mesylates Isoxsuprine | Metoclopramide Gilbepride Glyburide or Glibenclamide Short or fast-acting insulin (in a scheme according to capillary glycaemia) |
SMA-PEP.2019.006.LTS®). The following variables were collected: sex, age, ethnicity, comorbidities, prescription (at day 2 of hospital stay), and length of stay.

Elderly patients were those aged 65 years or older, and those aged 80 years or older were termed long-lived.

In addition, the Charlson index was also calculated from the collected data.

This work is part of project no. 22314819.4.0000.5479 approved by the Research Ethics Committee (CEP) of the institution where it was carried out.

Statistical analysis

Statistical analysis of the study population was based on the presence or absence of PIM in the patient’s prescription.

The Charlson index was also compared between groups of male and female patients, as well as between elderly and long-lived patients, for whom Pearson’s \( \chi^2 \) test was used with a significance level (alpha value) of 0.05.

RESULTS

A total of 142 patients (85 females and 57 males) with a mean age of 74.5±7.3 years (65–99 years) were analyzed. Of them, 108 (76.1%) were elderly and 34 (23.9%) were long-lived. The mean length of stay in the sample was 25.3±28.7 days (from 2 to 235 days), with 102 of the 142 analyzed patients having stayed at the hospital for up to 29 days.

Sixteen drugs considered PIM were found in the patients’ prescriptions (Table 1).

The elderly had a mean of 2.57±0.94 PIMs prescribed, whereas the long-lived patients had 2.56±0.89, with at least one PIM having been prescribed for 141 (99.3%) patients.

The Charlson index was calculated according to sex (female or male) and age (elderly or long-lived) of the sample (Table 3).

DISCUSSION

With aging, there occur losses to the functional reserve of multiple organs, which affects drug metabolism. PIMs for the elderly, therefore, are those whose use represents a greater potential risk than benefit for this population.

This, along with the global trend of an increasing number of elderly people, makes not only the identification but also the avoidance of PIM use in health institutions essential for preventing potentially negative outcomes, such as predictable adverse drug reactions, prolonged length of stay, and disabilities.

Literature data on PIM use, especially in developing countries, remain scarce, as does the analysis of the prevalence of these drugs in an in-hospital environment, since a significant portion of the studies focuses on institutionalized elderly patients or in outpatient care. This study, therefore, aims to address this gap.

Our sample showed significant percentages of PIM prescriptions, with 99.3% of them making use of at least one PIM. The prescription of some PIMs “as required” was also noted, which does not minimize their harmful risk, since in an in-hospital environment their use can become daily rather than episodic.

The drugs that were prescribed in our series are considered inappropriate due to the exacerbation of their mechanism of action in the elderly population. Thus, changes that are inherent to aging, such as reduced activation of enzymatic systems, lower concentration of plasma proteins, impaired renal function, and changes in body composition (in which case, the liposubstitution process alters the expected distribution of lipophilic drugs), contribute to greater bioavailability of such drugs and may result in actual doses exceeding the therapeutic dose that would be desired, therefore causing toxic effects.

Among the drugs identified, regular human insulin, omeprazole, and metoclopramide stand out as those most prescribed ones. The first is considered inappropriate when it is not used concomitantly with long-acting insulin, due to the increased risk of hypoglycemia and inappropriate management of hyperglycemia, which contributes to its long-term consequences.

It is noteworthy, however, that the health care service where our study was carried out began to implement a protocol for insulin prescription after our data collection had finished. Such a protocol eliminates the status of this drug as PIM, which can result in a significant reduction in its prescription.

In relation to metoclopramide, its contraindication is due to the risk of extrapyramidal symptoms. Dystonia and akathisia are symptoms that can occur following administration of a single dose of this drug, whereas conditions such as Tardive dyskinesia and secondary Parkinsonism tend to occur with sustained use.

### Table 3. Study population’s Charlson index.

| Charlson index | Sex (F/M) p=0.047* | Age (E/L) p=0.049* | Total |
|----------------|-------------------|-------------------|-------|
| Absence of comorbidity | 33 (39/18 (32) | 37 (35/14 (41) | 51 (36) |
| Low comorbidity | 32 (38/14 (25) | 31 (29/15 (44) | 46 (33) |
| High comorbidity | 20(23)/24 (43) | 39 (36)/5 (15) | 44 (31) |

F: female; M: male; E: elderly; L: long-lived.
The use of omeprazole, in turn, was associated with an increased risk of bone loss, falls and fractures, infection by *Clostridium difficile*, dementia, vitamin B12 deficiency, and kidney disease. It is worth mentioning that such effects have been reported when it was used in a chronic manner (at least one daily dose for 8 weeks)\(^1\), with its use being more relevant in the in-hospital environment for prolonged stays.

The Charlson index is a method for categorizing patients’ comorbidities that can be used as a prognostic tool for hospital mortality. The fact that in our study population, female and long-lived patients had better rates coincides with the tendency of these populations to have healthier lifestyle habits, in addition to seeking primary health care services more often, which allows for the prevention of diseases or screening thereof with an early treatment and hence better progression.

### CONCLUSIONS

This work has contributed to identifying the indiscriminate prescription of PIMs for the elderly population in tertiary health care centers. It thus serves as an alert to health care professionals about the importance of recognizing such indiscriminate use, assisting clinical practice, and optimizing patient care.

### AUTHORS’ CONTRIBUTIONS

**RMAFO:** Data curation, Formal Analysis, Writing – original draft. **MLG:** Conceptualization, Writing – review & editing. **RFR:** Conceptualization, Methodology, Writing – review & editing.

### REFERENCES

1. Nações Unidas Brasil. A ONU e as pessoas idosas. Brasília: ONU; 2019. [cited on Jan 07, 2022]. Available from: https://naoescunidas.org/acao/pessoas-idosas/

2. He W, Goodkind D, Kowal P. An aging world: 2015. International Population Reports. Census Burial. 2016;16(1):95. [cited on Jan 07, 2022]. Available from: https://www.census.gov/content/dam/Censushd16/04 Updates/01CurrentPopulationReports/InternationalPopulationReports/2015/01615.pdf

3. Carvalho Filho ET, Papaléo Netto M. Geriatria: fundamentos, clínica e terapêutica. 2nd ed. São Paulo: Atheneu; 2006.

4. Nunes BP, Soares MU, Wachs LS, Volz PM, Saes MO, Duro SMS, et al. Hospitalization in older adults: association with multimorbidity, primary health care and primary health plan. Rev Saude Publica. 2017;51:43.http://doi.org/10.1590/s1518-8787.2017051006646

5. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76. http://doi.org/10.1080/03602530902722679

6. Dutra MC, Uliano EJM, Machado DF, Martins T, Schueler-Trevisol F, Trevisol DJ. Avaliação da função renal em idosos: um estudo de base populacional. J Bras Nefrol 2014;36(3):297-303. http://doi.org/10.5935/0101-2800.20140043

7. Laroche ML, Charmes JP, Bouhier F, Merle L. Inappropriate medications in the elderly. Clin Pharmacol Ther. 2009;85(1):94-7. http://doi.org/10.1038/clpt.2008.214

8. Galli TB, Reis WC, Andrzejevski VM. Potentially inappropriate prescribing and the risk of adverse drug reactions in critically ill older adults. Pharm Pract (Granada). 2016;14(4):818. https://doi.org/10.18549/PHPPharmPract.2016.04.818

9. Gorzoni ML, Fabbrri RMA, Pires SL. Medicamentos potencialmente inapropriados para idosos. Rev Assoc Med Bras. 2012;58(4):442-6. http://doi.org/10.1590/S0104-42302012000400014

10. Ho HY, Lou MF. Introduction to tools for assessing medication use appropriateness in older adults. Hu Li Za Zhi. 2019;66(4):20-8. http://doi.org/10.6224/JN.201908_66(4).04

11. Lim YJ, Kim HY, Choi J, Lee J, Ahn AL, Oh EJ, et al. Potentially inappropriate medications by Beers criteria in older outpatients: prevalence and risk factors. Korean J Fam Med. 2016;37(6):329-33. http://doi.org/10.4082/kjfm.2016.37.6.329

12. Novaes PH, Cruz DT, Lucchetti ALG, Leite ICG, Lucchetti G. Comparison of four criteria for potentially inappropriate medications in Brazilian community-dwelling older adults. Geriatr Gerontol Int. 2017;17(10):1628-35. http://doi.org/10.1111/ggi.12944

13. Oliveira MG, Amorim WW, Oliveira CRB, Coqueiro HL, Gusmão LC, Passos LC. Brazilian consensus of potentially inappropriate medication for elderly people. Geriatr Gerontol Aging. 2016;10(4):168-81. https://doi.org/10.5327/22447-211520161600054

14. Matanović SM, Vlahović-Pallévski V. Potentially inappropriate prescribing to the elderly: comparison of new protocol to Beers criteria with relation to hospitalizations for ADRs. Eur J Clin Pharmacol. 2014;70(4):483-90. http://doi.org/10.1007/s00228-014-1648-3

15. 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-94. http://doi.org/10.1111/jgs.15767

16. Brasil. Agência Nacional de Vigilância Sanitária (ANVISA). Consulta a produtos regularizados. [cited on Oct 28, 2021]. Available from: https://consultas.anvisa.gov.br/#/medicamentos/

17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. http://doi.org/10.1016/0021-9681(87)90171-8

18. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol ver. 2004;56(2):163-84. http://doi.org/10.1124/pr.56.2.4

19. Maes ML, Fixen DR, Lineberry SA. Adverse effects of proton pump inhibitor use in older adults: a review of the evidence. Ther Adv Drug Saf. 2017;8(9):273-97.http://doi.org/10.1177/204209861715381